Skip to main content

Cardiovascular, Metabolic and Lipoprotein Translation

Section edited by Nehal N. Mehta and Tommaso Angelone
© Juan Gärtner/ stock.adob

This section aims to speed mechanistic understanding, development of novel diagnostics and potential therapeutic targets within cardiovascular, metabolic diseases and lipoprotein diseases. The section is open to experiments involving cellular models, animal models, observational studies and clinical trials that are distinguished for their novelty in approach, design or indication, timeliness, and unique ability to translate laboratory concepts from the bench to the bedside.

Highest priority will be given to those manuscripts which are specifically focused on cardiovascular, metabolic and lipid disorders which enrich understanding of disease mechanism, novel therapeutics and state-of-the-art scientific technique.

Featured articles

Immune cell phenotyping in low blood volumes for assessment of cardiovascular disease risk, development, and progression: a pilot study

Research | Yvonne Baumer et al

Comprehensive analysis of differential immunocyte infiltration and the potential ceRNA networks during epicardial adipose tissue development in congenital heart disease

Research | Li Ma et al

Extracellular vesicles in diabetes mellitus induce alterations in endothelial cell morphology and migration​​​​​​​

Research | Sharon F Wu et al

Page 6 of 6

  1. Serum thiols have shown associations with surrogate markers of cardiovascular disease. However, little information is available on their combined association with validated cardiovascular risk scores for prima...

    Authors: Arduino A Mangoni, Angelo Zinellu, Ciriaco Carru, John R Attia and Marc McEvoy
    Citation: Journal of Translational Medicine 2013 11:99
  2. Sevoflurane is an anesthetic agent which also participates in protective mechanisms in sepsis, likely due to anti-inflammatory properties. A key tissue in sepsis is the endothelium, which expresses TLR2 and TL...

    Authors: Raquel Rodríguez-González, Aurora Baluja, Sonia Veiras Del Río, Alfonso Rodríguez, Jaime Rodríguez, Manuel Taboada, David Brea and Julián Álvarez
    Citation: Journal of Translational Medicine 2013 11:87
  3. Lixisenatide is a glucagon-like peptide-1 analog which stimulates insulin secretion and inhibits glucagon secretion and gastric emptying. We investigated cardioprotective effects of lixisenatide in rodent mode...

    Authors: Paulus Wohlfart, Wolfgang Linz, Thomas Hübschle, Dominik Linz, Jochen Huber, Sibylle Hess, Daniel Crowther, Ulrich Werner and Hartmut Ruetten
    Citation: Journal of Translational Medicine 2013 11:84
  4. Ritonavir is a HIV protease inhibitor. In addition to its antiviral effect, Ritonavir directly inhibits the insulin-regulated glucose transporter GLUT4 and blocks glucose entry into fat and muscle cells. Howev...

    Authors: Prachi Gupta, Abhinav Kanwal, Uday Kumar Putcha, Yogesh Bulani, Bhavesh Sojitra, Tarak Nath Khatua, Madhusudana Kuncha and Sanjay Kumar Banerjee
    Citation: Journal of Translational Medicine 2013 11:80
  5. Race- and gender-variation in innate immunity may contribute to demographic differences in inflammatory and cardiometabolic disease; yet their influence on dynamic responses during inflammatory stress is poorl...

    Authors: Jane F Ferguson, Parth N Patel, Rhia Y Shah, Claire K Mulvey, Ram Gadi, Prabhjot S Nijjar, Haris M Usman, Nehal N Mehta, Rachana Shah, Stephen R Master, Kathleen J Propert and Muredach P Reilly
    Citation: Journal of Translational Medicine 2013 11:63
  6. This pilot study investigated the association between heat shock protein 70 (HSP70) and anti-HSP70 antibodies as well as their changes and rhythm outcome after atrial fibrillation (AF) catheter ablation.

    Authors: Jelena Kornej, Claudia Reinhardt, Jedrzej Kosiuk, Arash Arya, Gerhard Hindricks, Volker Adams, Daniela Husser and Andreas Bollmann
    Citation: Journal of Translational Medicine 2013 11:49
  7. Left ventricular (LV) remodeling following large transmural myocardial infarction (MI) remains a pivotal clinical issue despite the advance of medical treatment over the past few decades. Identification of new...

    Authors: Yue-Feng Chen, Nathan Y Weltman, Xiang Li, Steven Youmans, David Krause and Anthony Martin Gerdes
    Citation: Journal of Translational Medicine 2013 11:40
  8. Recently, the high-mobility group A1 gene (HMGA1) variant IVS5-13insC has been associated with type 2 diabetes, but reported associations are inconsistent and data are lacking in Hispanic and African American pop...

    Authors: Jason H Karnes, Taimour Y Langaee, Caitrin W McDonough, Shin-Wen Chang, Miguel Ramos, James R Catlin Jr, Octavio E Casanova, Yan Gong, Carl J Pepine, Julie A Johnson and Rhonda M Cooper-DeHoff
    Citation: Journal of Translational Medicine 2013 11:12
  9. Increasing evidences have suggested that autoantibodies against muscarinic-2 acetylcholine receptor (anti-M2-R) may play an important role in the development of atrial fibrillation (AF). Predictive value of pre-p...

    Authors: Changhong Zou, Zhiyong Zhang, Wenmin Zhao, Guang Li, Guiling Ma, Xinchun Yang, Jianjun Zhang and Lin Zhang
    Citation: Journal of Translational Medicine 2013 11:7
  10. Atherosclerosis is an inflammatory process of the arterial walls and is initiated by endothelial dysfunction accompanied by an imbalance in the production of reactive oxygen species (ROS) and nitric oxide (NO)...

    Authors: Camille M Balarini, Marcos A Leal, Isabele B S Gomes, Thiago M C Pereira, Agata L Gava, Silvana S Meyrelles and Elisardo C Vasquez
    Citation: Journal of Translational Medicine 2013 11:3
  11. The additive effects of obesity and metabolic syndrome on left ventricular (LV) maladaptive remodeling and function in hypertension are not characterized.

    Authors: Dominik Linz, Mathias Hohl, Felix Mahfoud, Jan-Christian Reil, Wolfgang Linz, Thomas Hübschle, Hans-Paul Juretschke, Claudia Neumann-Häflin, Hartmut Rütten and Michael Böhm
    Citation: Journal of Translational Medicine 2012 10:187

Annual Journal Metrics

  • 2022 Citation Impact
    7.4 - 2-year Impact Factor
    6.9 - 5-year Impact Factor
    1.458 - SNIP (Source Normalized Impact per Paper)
    1.544 - SJR (SCImago Journal Rank)

    2022 Speed
    10 days submission to first editorial decision for all manuscripts (Median)
    84 days submission to accept (Median)

    2022 Usage 
    32,614 Altmetric mentions